- Home
- EONR vs KPRX Comparison
EONR vs KPRX Comparison
Compare EONR & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EONR
- KPRX
- Stock Information
- Founded
- EONR 2020
- KPRX 1998
- Country
- EONR United States
- KPRX United States
- Employees
- EONR N/A
- KPRX N/A
- Industry
- EONR
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- EONR
- KPRX Health Care
- Exchange
- EONR NYSE
- KPRX Nasdaq
- Market Cap
- EONR 10.7M
- KPRX 11.0M
- IPO Year
- EONR N/A
- KPRX N/A
- Fundamental
- Price
- EONR $0.99
- KPRX $3.29
- Analyst Decision
- EONR
- KPRX Strong Buy
- Analyst Count
- EONR 0
- KPRX 1
- Target Price
- EONR N/A
- KPRX $10.00
- AVG Volume (30 Days)
- EONR 319.0K
- KPRX 46.8K
- Earning Date
- EONR 11-26-2024
- KPRX 11-26-2024
- Dividend Yield
- EONR N/A
- KPRX N/A
- EPS Growth
- EONR N/A
- KPRX N/A
- EPS
- EONR N/A
- KPRX 1.53
- Revenue
- EONR $28,248,512.00
- KPRX $16,020,000.00
- Revenue This Year
- EONR N/A
- KPRX N/A
- Revenue Next Year
- EONR N/A
- KPRX N/A
- P/E Ratio
- EONR N/A
- KPRX $2.15
- Revenue Growth
- EONR N/A
- KPRX N/A
- 52 Week Low
- EONR $0.81
- KPRX $3.00
- 52 Week High
- EONR $7.80
- KPRX $8.98
- Technical
- Relative Strength Index (RSI)
- EONR N/A
- KPRX 41.12
- Support Level
- EONR N/A
- KPRX $3.47
- Resistance Level
- EONR N/A
- KPRX $3.75
- Average True Range (ATR)
- EONR 0.00
- KPRX 0.23
- MACD
- EONR 0.00
- KPRX -0.03
- Stochastic Oscillator
- EONR 0.00
- KPRX 15.06
About EONR EON RESOURCES INC
EON Resources Inc is an independent upstream energy company focused on maximizing total returns to its shareholders through the development of onshore oil and natural gas properties in the United States. Its current focus is as an upstream energy company producing oil and gas properties in the Permian Basin.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.